BiovelocITA invests 680.000 euro in Amypopharma, a spin-off of the University of Milan-Bicocca

The mission of Amypopharma is the development of nanoparticles for the treatment of amyloidosis, severe diseases currently lacking effective therapies.

Download the Press release